RxDoctor Payments Data

Christina Powers, MD

Internal Medicine · Canton, GANPI 1073932414

Payments from drug & device makers

$3,639in general payments, 2019–2025

Across 186 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$778
  • AbbVie$729
  • Lilly USA, LLC$446
  • Novo Nordisk$440
  • Pfizer$403
  • Sumitomo Pharma America, Inc.$139
  • plus $703 from 13 others

What the payments were for

  • Food & beverage$3,639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,639 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$115,250
Medicare patients
385
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$206,891
JardianceEmpagliflozin27$41,071
TrulicityDulaglutide22$32,390
MounjaroTirzepatide17$20,132
FarxigaDapagliflozin Propanediol15$15,009
RybelsusSemaglutide11$14,298
Fenofibrate26$8,345
SynthroidLevothyroxine Sodium78$7,039
Dexlansoprazole DrDexlansoprazole21$4,559
Levothyroxine Sodium363$4,090
Duloxetine Hcl70$3,232
Atorvastatin Calcium367$2,471
Pantoprazole Sodium137$2,101
Ezetimibe46$1,863
Bupropion XlBupropion Hcl98$1,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$440$221,188133 claims
Lilly USA, LLCTrulicity, Mounjaro$446$52,52239 claims
AstraZenecaFarxiga$778$15,00915 claims
AbbVieSynthroid$729$7,03978 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →